Menu Search
Equities

RadNet Inc

PQIA:FRA

RadNet Inc

Actions
  • Price (EUR)77.50
  • Today's Change-0.50 / -0.64%
  • Shares traded366.00
  • 1 Year change+163.61%
  • Beta--
Data delayed at least 15 minutes, as of Nov 26 2024 07:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

RadNet, Inc. is a national provider of fixed-site diagnostic imaging services and related information technology solutions (including artificial intelligence) in the United States. It has a network of 366 owned and/or operated outpatient imaging centers. The Company’s Imaging Center segment provides physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders. Its services include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, diagnostic radiology (X-ray), fluoroscopy and other related procedures. The Company’s Artificial Intelligence (AI) segment develops and deploys clinical applications to enhance interpretation of medical images and improve patient outcomes with an emphasis on brain, breast, prostate and pulmonary diagnostics. The Company, through its joint ventured Arizona Diagnostic Radiology Group, LLC, owns seven outpatient imaging centers.

  • Revenue in USD (TTM)1.77bn
  • Net income in USD-4.41m
  • Incorporated2008
  • Employees7.87k
  • Location
    RadNet Inc1510 Cotner AveLOS ANGELES 90025United StatesUSA
  • Phone+1 (310) 478-7808
  • Fax+1 (302) 636-5454
  • Websitehttps://www.radnet.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		RDNT:NMQ since
announced		Transaction
value
Houston Medical Imaging LLCAnnounced21 Feb 202421 Feb 2024Announced115.80%--
Data delayed at least 15 minutes, as of Nov 25 2024 20:59 GMT.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.